Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Mohammed S Salahudeen
 + 1631 word(s) 1631 2022-02-07 07:01:19 |
2 format corrected.
Beatrix Zheng
 + 2179 word(s) 3810 2022-02-08 02:24:12 | |
3 Move out of the entry collection "MedlinePlus" as MedlinePlus is an online resource.
Beatrix Zheng
 Meta information modification 3810 2022-02-08 04:50:27 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Salahudeen, M.S. Improving the Anticholinergic Prescribing Practice in Older Adults. Encyclopedia. Available online: https://encyclopedia.pub/entry/19189 (accessed on 17 May 2024).
Salahudeen MS. Improving the Anticholinergic Prescribing Practice in Older Adults. Encyclopedia. Available at: https://encyclopedia.pub/entry/19189. Accessed May 17, 2024.
Salahudeen, Mohammed S. "Improving the Anticholinergic Prescribing Practice in Older Adults" Encyclopedia, https://encyclopedia.pub/entry/19189 (accessed May 17, 2024).
Salahudeen, M.S. (2022, February 07). Improving the Anticholinergic Prescribing Practice in Older Adults. In Encyclopedia. https://encyclopedia.pub/entry/19189
Salahudeen, Mohammed S. "Improving the Anticholinergic Prescribing Practice in Older Adults." Encyclopedia. Web. 07 February, 2022.
Improving the Anticholinergic Prescribing Practice in Older Adults
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11030714

Healthcare practitioner-oriented interventions have the potential to reduce the occurrence of anticholinergic prescribing errors in older people. Interventions were primarily effective in reducing the burden of anticholinergic medications and assisting with deprescribing anticholinergic medications in older adults. 

anticholinergics intervention prescribing older people

1. Introduction

Prescribing medications among older adults is recognised as a challenging task and an essential practice that needs to be continuously monitored, assessed, and refined accordingly. Moreover, it is based on understanding clinical pharmacology principles, knowledge about medicines, and particularly the experience and empirical knowledge of the prescribers [1][2]. Clinicians face several challenges while prescribing medications among older adults, and the prescribing of potentially inappropriate medications (PIMs) for this age group is prevalent [3]. The available epidemiological data show that up to 20% of older patients in outpatient settings and 59% of hospitalised older patients consume at least one PIM [4][5][6][7][8]. Adverse effects in older people due to inappropriate prescribing are prevalent, leading to increased hospital admissions and mortality [9].
Medications that possess anticholinergic activity are a class of PIMs widely prescribed for various clinical conditions in older adults [10][11]. Older people are particularly vulnerable to the adverse effects from medicines with anticholinergic-type effects [12][13]. Most medications commonly prescribed to older people are not routinely recognised as having anticholinergic activity, and empirically, clinicians prescribe these medicines based on their anticipated therapeutic benefits while overlooking the risk of cumulative anticholinergic burden [14][15][16]. Anticholinergic burden refers to the cumulative effect of taking multiple medications with anticholinergic activity [17][18]. There is no gold standard approach available to quantify and determine whether an acceptable range of anticholinergic drug burden exists in older adults [19][20]. The central adverse effects of anticholinergic medications are attributed to the excess blocking of cholinergic receptors within the central nervous system (CNS) [16]. The commonly reported central adverse effects are cognitive impairment, headache, reduced cognitive function, anxiety, and behavioural disturbances [16]. The common peripheral adverse effects of anticholinergic medications are hyperthermia, reduced saliva and tear production, urinary retention, constipation, and tachycardia [16].
Anticholinergic medications are associated with poor outcomes in older patients, but there is no specific intervention strategy for reducing anticholinergic drug exposure [21]. There is little evidence that medication review could be a promising strategy in reducing the drug burden in older people [22][23]. Medical practitioner-led and pharmacist-led medication reviews have earlier been reported as a standard practice for reducing anticholinergic drug exposure [24][25]. Pharmacist-led medication review has recently been found to be ineffective among older patients of the Northern Netherlands [25]. A few meta-analyses have also reported the lack of effectiveness of different types of medication reviews on mortality and hospitalisation outcomes [26][27][28]. Multidisciplinary strategies such as patient-centred, pharmacist–physician intervention are also recognised as promising for improving medication use in older patients at risk [29]. Another intervention strategy, i.e., the SÄKLÄK project, had some effects on the PIMs prescription and reduced potential medication-related problems [30]. The SÄKLÄK project is a multi-professional intervention model to improve medication use in older people [30], and it consists of self-assessment using a questionnaire, peer-reviewed by experienced healthcare professionals, feedback report provided by experienced healthcare professionals, and an improvement plan [30].
Interventions to improve prescribing practice more generally have been the subject of many studies and are frequently targeted according to the type of error [31][32]. It is crucial to explore which interventions have effectively changed prescribing practices and optimised patient outcomes while minimising healthcare costs. However, little is known about the effectiveness of existing interventions at improving the anticholinergic prescribing practice for older adults.

2. Analysis on Research Results

The primary electronic search identified a total of 3168 studies from the five databases. Using EndNote X9 (Thomson Reuters), we eliminated 350 duplicate studies, and the remaining 2818 studies were examined to determine their relevance for inclusion. Of those, only 70 were found to be eligible for full-text analysis. Subsequently, 47 studies were excluded as they failed to meet the predefined inclusion criteria. No potential studies were identified from the citation analysis. Finally, a total of 23 studies that investigated the effectiveness of anticholinergic prescribing practice in older adults were included in this review (Figure 1).
Jcm 11 00714 g001 550
Figure 1. PRISMA flow diagram of the study selection process and citation analysis.

2.1. Overview of the Included Studies

Table 1 provides the qualitative summary of the included studies, mainly showcasing the type of interventions, and Table 2 illustrates an overview of the quantitative summary of the studies based on study design, setting, sample size, study duration and follow-up, outcome measure (control/pre and intervention/post), significant association (+ or −), and statistical tests.
The countries of origin were USA (n = 5) [29][33][34][35][36], Australia (n = 4) [22][23][37][38], Finland (n = 2) [39][40], Norway (n = 2) [21][41], Ireland [42], New Zealand [43], Belgium [44], Spain [45], Sweden [46], Sweden [30], France [47], Italy [48], Taiwan [49], and The Netherlands [50].
The study settings included hospitals (n = 7) [35][36][39][41][45][47][48] community/primary care (n = 7) [22][30][33][42][44][46][50] and nursing homes/aged care facilities (n = 9) [21][23][29][34][37][38][40][43][49]. There were ten cross-sectional studies [22][33][35][37][38][39][41][46][47][49], six nonrandomised or pre/post studies [30][34][42][43][45][48], and seven RCTs [21][23][29][36][40][44][50]. The studies included in this study had sample sizes ranging from 46 to 46,078 study subjects. The average age of the participants varied between 65 and 87.5 years, and the proportion of the female subjects was 39.0–77%.
Table 1. The qualitative summary of included studies.
Author, Year, Country Study Design Intervention Description of Intervention(s) Effect on Outcome/Key Findings
Riordan et al., 2019, Ireland [42] Convergent parallel mixed-methods design (before and after) Academic Detailing (pharmacist-led) Pharmacist conducted face-to-face education
sessions and small focus group academic detailing sessions of 19–48 min with physicians.		 Pharmacist-led academic detailing intervention was acceptable to GPs.
Behavioural Change: awareness of non-pharmacological methods in treating urinary incontinence.
Knowledge Gain: intervention served to refresh their knowledge
Ailabouni et al., 2019, New Zealand [43] A single group (pre-and post-comparison) feasibility study Medication review (deprescribing) A collaborative pharmacist-led medication review with GPs was employed.
New Zealand registered pharmacists used peer-reviewed deprescribing guidelines. The cumulative use of anticholinergic and sedative medicines for each participant was quantified using the DBI.		 Deprescribing resulted in a significant reduction in falls, depression and frailty scores, and adverse drug reactions. No improvement in cognition and quality of life.
Total regular medicines use reduced statistically, by a mean difference of 2.13 medicines per patient, among patients where deprescribing was initiated.
Toivo et al., 2019, Belgium [44] Cluster RCT Care coordination intervention (coordinated medication risk management) Practical nurses were trained to make the preliminary medication risk assessment during home visits and report findings to the coordinating pharmacist. The coordinating pharmacist prepared the cases for the triage meeting with the physician and home care nurse to decide further actions. No significant impact on the medication risks between the intervention and the control group.
The per-protocol analysis indicated a tendency for effectiveness, particularly in optimising central nervous system medication use.
Hernandez et al., 2020, Spain [45] Prospective pre-and post- interventional study Medication review Pharmacists reviewed the medications and detected drug-related problems using the Drug Burden Index (DBI) tool. Their recommendations were communicated to the physician via telephone, weekly meetings, and email. Further review was conducted at the weekly meeting between physician and pharmacist. Statistically significant differences were found between pre- and post-intervention in NPI at admission, drug-related problems, MAI criteria (interactions, dosage and duplication), and mean (SD) DBI score.
Lenander et al., 2018, Sweden [46] Cross-sectional Medication Review Clinical Pharmacist led medication review to assess the prevalence of DRPs and recommendations to discontinue, followed by team-based discussions with general practitioners (GPs) and nurses It shows that the medication reviews decreased the use of potentially inappropriate medication.
Weichert et al., 2018, Finland [39] Multicentre observational study Medication Review Medication review was conducted for ACB in patients at the time of admission and discharge 21.1% of patients had their ACB reduced. There is considerable scope for improvement of prescribing practices in older people.
Lenander et al., 2017, Sweden [30] Interventional pilot study SÄKLÄK project, a developed intervention model Multi-professional intervention model created to improve medication safety for elderly Significant decrease in the prescription of anticholinergic drugs indicated the SÄKLÄK intervention is effective in reducing potential DRPs
Moga et al., 2017,
USA [29]		 Parallel arm Randomised Interventional study Targeted medication therapy management intervention Targeted patient-centred pharmacist–physician team medication therapy management intervention was used to reduce the use of inappropriate anticholinergic medications in older patients. The targeted medication therapy management intervention resulted in improvement in anticholinergic medication appropriateness and reduced the use of inappropriate anticholinergic medications in older patients.
Lagrange et al., 2017, France [47] Retrospective study A context-aware pharmaceutical analysis tool A context-aware computerised decision-support system designed to automatically compare prescriptions recorded in computerised patient files against the main consensual guidelines for medical management in older adults. Prescription of anticholinergics was significantly decreased (28%).
Carnahan et al., 2017, USA [34] Quasi-experimental study design Educational program on medication use IA-ADAPT/CMS Partnership is an evidence-based training program to improve dispensing drugs for elderly Suggests that the IA-ADAPT and the CMS Partnership improved medication use with no adverse impact on BPSD.
Hanus et al., 2016, USA [35] Observational Pilot study Pharmacist-led EHR-based population health initiative and ARS Service Physicians in the primary care settings could communicate with pharmacists employing a shared EHR.
As part of a quality improvement project, a pharmacist-led EHR-based medication therapy recommendation service was implemented at 2 DHS medical clinics to reduce the anticholinergic burden		 High recommendation acceptance rates were achieved using objective anticholinergic risk assessment and algorithm-driven medication therapy recommendations.
McLarin et al., 2016, Australia [38] Retrospective study RMMR Impact of RMMRs on anticholinergic burden quantified by seven anticholinergic risk scales Demonstrated that RMMRs are effective in reducing ACM prescribing in elderly
Kersten et al., 2015, Norway [41] Retrospective study Medication review Investigated the clinical impact of PIMs in acutely hospitalised older adults. Anticholinergic prescriptions were reduced from 39.2% to 37.9%
Juola et al., 2015, Finland [40] Cluster RCT Educational intervention Nursing staff working in the intervention wards received two 4-h interactive training sessions based on constructive learning theory to recognise harmful medications and adverse drug events. No significant differences in the change in prevalence of anticholinergic drugs.
Kersten et al., 2013, Norway [21] RCT Multidisciplinary drug review Single Blind MDRD was conducted that recruited long-term nursing home residents with a total ADS score of greater than or equal to 3 After 8 weeks, the median ADS score was significantly reduced from 4 to 2 in the intervention group. The largest improvement in immediate recall after 8 weeks was observed in the five patients in the intervention group who had their ADS score reduced to 0
Ghibelli et al., 2013, Italy [48] Pre, post-intervention study INTERcheck CPSS INTERcheck is a CPSS developed to optimise drug prescription for older people with multimorbidity and minimise the occurrence of adverse drug reactions. The use of INTERCheck was associated with a significant reduction in PIMs and new-onset potentially severe DDIs.
Yeh et al., 2013, Taiwan [49] Prospective case-control study Educational program for primary care physicians Educational program for primary care physicians serving in Veterans’ Homes, focusing on anticholinergic adverse reactions in geriatrics and the CR-ACHS CR-ACHS was significantly reduced in the intervention group at 12-week follow-up.
Boustani et al., 2012, USA [36] RCT CDSS Alert (anticholinergic discontinuation) CDSS alert system sends an interruptive alert if any of the 18 anticholinergics were prescribed, recommending stopping the drug, suggesting an alternative, or recommending dose modification. Physicians receiving the CDSS issued more discontinuation orders of definite anticholinergics, but the results were not statistically significant. Results suggest that human interaction may play an important role in accepting recommendations aimed at improving the care of hospitalised older adults with CI.
Gnjidic et al., 2010, Australia [23] Cluster RCT Medication review The study intervention included a letter and phone call to GPs, using DBI to prompt them to consider dose reduction or cessation of anticholinergic and sedative medications. At follow-up, a DBI change was observed in 16 participants. DBI decreased in 12 participants, 6 (19%) in the control group, and 6 (32%) in the intervention group.
Castelino et al., 2010, Australia [22] Retrospective study Medication reviews by pharmacist HMR by pharmacists for leads to an improvement in the use of medications DBI and PIMs identified in 60.5% and 39.8% of the patients. Significant reduction in the cumulative DBI scores for all patients was observed following pharmacists’ recommendations
Starner et al., 2009, USA [33] Retrospective study Educational Intervention Intervention letters were mailed to the physicians for patients having ≥1 DAE claim Noticeable decrease was observed after a 6-month follow-up of the intervention in the reduction of DAE claims (48.8%) specifically reduction of anticholinergics (66.7%) was highest
Nishtala et al., 2009, Australia [37] Retrospective study RMMR Clinical Pharmacist-led medication review decreased the DBI in older people GP’s uptake of recommendations made by pharmacists resulted in a decrease in DBI score. Clinical pharmacist-conducted medication reviews can reduce prescribing of anticholinergic drugs and significantly decrease the DBI score of the study population.
van Eijk et al., 2001, Netherlands [50] RCT Educational visits as an individual and a group for
general practitioners and pharmacists		 Educational visits used academic detailing to discuss prescribing of highly anticholinergic antidepressants in elderly people. The rate of starting anticholinergic antidepressants in the elderly reduced 26% (in the individual intervention) and 45% (in the group intervention)
The use of less anticholinergic antidepressants increased by 40% and 29%, respectively
MAI, medication appropriateness index; GPs, general practitioners; DBI, drug burden index; NPI, neuropsychiatry inventory; RCT, randomised controlled trial; CDSS, clinical decision support system alert; DAE, drugs to be avoided in the elderly; DRPs, drug-related problems; CI, cognitive impairment; ACB, anticholinergic burden; MDRD, modification of diet in renal disease study equation; ADS, anticholinergic drug scale; PIMs, potentially inappropriate medications; CPSS, computerised prescription support system; DDIs, drug–drug interactions; EHR, electronic health record; DHS, Department of Health Services; ARS, anticholinergic risk scale; CR-ACHS, clinician-rated anticholinergic score; HMR, home medicines review; IA-ADAPT, improving antipsychotic appropriateness in dementia patients; CMS, Centers for Medicare and Medicaid Services Partnership to Improve Dementia Care; BPSD, Behavioural and psychological symptoms of dementia; RMMRs, Residential Medication Management Reviews; ACM, anticholinergic medication.
 
 
Table 2. The quantitative summary of included studies.
Author, Year,
Country		 Study Design Setting Sample Size Mean Age (Years) Gender (Female %) Study Duration Follow-Up Relevant
Outcome(s)		 Outcome Measure Significant
Association (±)		 Statistical Tests
Control/Pre Intervention/Post
Riordan et al., 2019, Ireland [42] Convergent parallel mixed-methods design (before and after) General Practice 154 75.0 72.1 5 months 6 months Effects on DBI and ACB scores Patients having an ACB score of 0 (34%) Patients having an ACB score of 0 (31%)
65% of patients did not show any change
in DBI over time		 − SD, Range, IQR, Frequency, Percentages
Ailabouni et al., 2019, New Zealand [43] A single group (pre- and post-comparison) feasibility study Residential care facilities 46 65.0 74.0 6 months 2 weeks Reduction in DBI score ≥0.5 (median DBI) 0.34 (median DBI) + Wilcox-signed Rank test (WSR)
t-test
Fisher’s exact test
Toivo et al., 2019, Belgium [44] Cluster RCT Primary care 129 82.8 69.8 1 year 1 year Anticholinergic use 18.8% (Anticholinergic use at baseline)
18.8% (Anticholinergic use at 12 months)		 29.6% (Anticholinergic use at baseline)
18.5% (Anticholinergic use at 12 months)		 − Binary logistic regression, two-sided statistical tests
Hernandez et al., 2020, Spain [45] Prospective pre- and post-interventional study Intermediate care hospital 55 84.6 60.0 12 months NA Anticholinergic burden per Drug Burden Index (DBI) 1.38 ± 0.7
(Mean DBI)		 1.08 ± 0.7
(Mean DBI)		 + Kolmogorov–Smirnov test
Student’s t-test
Lenander et al., 2018, Sweden [46] Cross-sectional Primary care 1720 87.5 74.5 1 year 8 weeks Discontinuation of DRPs Pts with anticholinergics = 9.2% Pts with anticholinergics = 4.2% + Student’s t-test, Chi-square
Weichert et al., 2018, Finland [39] Observational study Hospital 549 79.6 58.3 1 year, 5 months 30 days Reduction in ACB Score during the hospital stay Patients on DAPs on admission = 60.8% Patients on DAPs on discharge = 57.7 − Shapiro–Wilk test, Wilcoxon signed-rank test,2 sample t-test, Yates and Pearson’s chi-square test multivariate binary logistic regression
Lenander et al., 2017 Sweden [30] Interventional pilot study Primary care 2400 to 13,700 patients (estimated) 65–79 (range) 63 9 months 6 months Reduction in anticholinergic PIMs (before/after) Anticholinergic prescriptions before intervention (4513) Anticholinergic prescriptions after intervention (3824) + Chi-square test
Moga et al., 2017, USA [29] Parallel arm Randomised Interventional study Alzheimer’s Disease Center 49 77.7 ± 6.6 70.0 1 year 8 weeks Significant reduction in anticholinergic drug scale (ADS) Score 1.0 (0.3) 0.2 (0.3) + Student’s t-tests (or Wilcoxon rank-sum tests for non-normally distributed variables),
Chi-square or Fisher’s exact tests
Lagrange et al., 2017, France [47] Retrospective study Hospital 187 73.9 63.1 10.5 months 33 and 37 days Change in number of prescriptions 6538 doses
(Anticholinergics)		 4696 doses
(Anticholinergics)		 + Descriptive statistics
Carnahan et al., 2017, USA [34] Quasi-experimental study design Nursing home 411 86.7 77.0 1 year 9 months 276 days Anticholinergic use Mean (SD)
35.9% (12.0%)		 Mean (SD)
36.1% (10.9%)		 − Generalised linear mixed logistic regression
Antipsychotic use Mean (SD)
17.7% (10.4%)		 Mean (SD)
20.7% (10.6%)		 +
Hanus et al., 2016, USA [35] Observational Pilot study Medical clinics 59 77 ± 9.3 51.0 2 months 2 weeks Reduction in ACB Score,
Increased medication acceptance rate		 1.08
50%		 0.89
95%		 + Generalised linear mixed-effects model, paired t-test
McLarin et al., 2016, Australia [38] Retrospective study. Aged care facilities 814 85.6 69.6 NA NA Reduction in anticholinergic medications after a medication review Mean (SD)
3.73 (1.46)		 Mean (SD)
3.32 (1.7)		 + Wilcoxon signed-rank test, ANOVA
Kersten et al., 2015, Norway [41] Retrospective study Hospital 232 86.1 59.1 8 months 1 year Reduction in anticholinergic prescriptions Prevalence of anticholinergic drugs was significantly reduced (p < 0.02) + Paired samples Student’s t-test, McNamar’s test, Mann–Whitney U tests, ANOVA, linear regression
Juola et al., 2015, Finland [40] Cluster RCT Assisted living facilities 227 83.0 70.9 1 year 1 year Mean Anticholinergic drugs 1.0
(Mean Anticholinergic drugs)		 1.2
(Mean Anticholinergic drugs)		 − t-tests, Mann–Whitney U tests, or Chi-square tests, GEE models, Poisson regression models
Kersten et al., 2013, Norway [21] RCT Nursing home 87 85.0 39.0 8 weeks 8 weeks Marked reduction in ADS score Median = 4 Median = 2 + ANCOVA, Poisson regression analysis
Ghibelli et al., 2013, Italy [48] Pre- and post-intervention study Hospital 75 for Pre
75 for Post		 81 58.3 4 months NA Reduction in ACB score 1.3 1.1 − Pearson Chi-square test, Student’s t-test
Yeh et al., 2013, Taiwan [49] Prospective case-control Veteran Home 67 83.4 NA 12 weeks 12 weeks Anticholinergic Burden (CR-ACHS) 1.0 ± 1.1
(Mean CR-ACHS)		 −0.5 ± 1.1
(Mean CR-ACHS)		 + Wilcoxon signed ranks test
Boustani et al.,2012, USA [36] RCT Hospital 424 74.8 68.0 21 months At the time of discharge Discontinuation of AC prescriptions anticholinergic discontinued = 31.2% anticholinergic discontinued = 48.9% _ Fisher’s exact test, t-test, logistic regression, multiple regression
Gnjidic et al., 2010, Australia [23] Cluster RCT Self-care retirement village 115 84.3 73.0 13 months 3 months Drug Burden Index (DBI) 0.26 ± 0.34 (mean DBI) 0.22 ± 0.42 (mean DBI) − Kolmogorov–Smirnov test
Mann–Whitney nonparametric test
X2 test
Castelino et al., 2010, Australia [22] A retrospective analysis of medication reviews Community-dwelling 372 76.1 55.0 NA NA Impact of pharmacist’s on DBI scores Sum of DBI scores = 206.86 Sum of DBI scores = 157.26 + Wilcoxon signed-rank test
Starner et al., 2009, USA [33] Retrospective study Pharmacy claims data 10,364 65.0 NA 8 months 6 months Rate of discontinued anticholinergics NA 66.7% + NA
Nishtala et al., 2009, Australia [37] Retrospective study Aged care homes 500 84.0 75.0 6 months 2 months Significant decrease in DBI score NA 12% decrease in DBI + 2-tailed Wilcoxon signed-rank test
van Eijk et al., 2001, Netherlands [50] RCT Primary care 46,078 71 58.0 1 year NA Reduction in the prescribing of anticholinergics 30% reduction in the rate of starting highly anticholinergic antidepressant in the individual intervention arms compared with the control arm 40% reduction in the rate of starting highly anticholinergic antidepressants in the group intervention arms compared with the control arm + Poisson regression model
RCT, randomised controlled trial; DBI, drug burden index; DRPs, drug-related problems; ACB, anticholinergic burden; PIM, potentially inappropriate medications; WSR, Wilcox-signed rank test; SD, standard deviation; GPs, general practitioner; CR-ACHS, clinician-rated anticholinergic score; and NA, not available.

 

2.2. Methodological Quality of Studies

All eligible studies were rated for their methodological quality, and many studies (n = 14, 61%) were identified to be of good quality based on the Newcastle-Ottawa scale [22][30][33][34][37][38][39][41][42][43][45][46][47][48] (Table S2). The quality of the RCTs was critically appraised using the Cochrane risk of bias assessment tool as shown in Supplementary Table S3. There was a general lack of adequate blinding between study subjects and healthcare practitioners, and between outcomes and assessors. Nonetheless, the follow-up duration was either not clearly specified or insufficient (less than six months) in many studies [21][22][23][29][35][36][37][38][39][43][45][46][47][48][49][50]. Altogether, the studies had a duration of follow-up ranging from 14 days [35][43] to 1 year [40][41][44] (Table 2).

2.3. Intervention Characteristics

All studies tested single-component interventions, and medication review was the most common single-component healthcare practitioner-oriented intervention [21][22][23][37][38][39][41][43][45][46][49] followed by the provision of education to the healthcare practitioners [33][34][40][42][49][50]. Healthcare practitioners conducted medication reviews using patient notes or tools such as drug burden index (DBI) and anticholinergic burden (ACB) [23][37][38][39][43][45]. Pharmacists implemented interventions without collaboration with other healthcare practitioners in nearly half of the studies (n = 11).
Healthcare practitioner-initiated education mainly consisted of professional components, such as academic detailing sessions for physicians [42][49][50], evidence-based training programs to improve dispensing [34], interactive training sessions for nurses [40], and mailing of intervention letters to the physicians [33]. In three studies [21][29][30], healthcare practitioners also performed interventions such as targeted patient-centred, pharmacist–physician team medication therapy management (MTM) intervention, SÄKLÄK project, and multidisciplinary medication review in collaborations with other healthcare practitioners. A context-aware pharmaceutical analysis tool was tested in France to automatically compare prescriptions recorded in computerised patient files against the main consensual guidelines [47]. Another study tested the clinical decision support system to discontinue orders of definite anticholinergic medications for hospitalised patients with cognitive impairment [36]. Similarly, a study tested targeted patient-centred pharmacist–physician team MTM intervention to reduce the consumption of inappropriate anticholinergic medications in older patients [29]. In Italy, researchers tested the INTERcheck computerised prescription support system to optimise drug prescriptions and minimise the occurrence of adverse drug reactions [48].

2.4. Effectiveness of Interventions at Improving Anticholinergic Prescribing Practice

Sixteen studies (70%) [21][22][29][30][33][34][35][37][38][41][43][45][46][47][49][50] investigating a healthcare practitioner-oriented intervention reported a significant reduction in anticholinergic prescribing errors, whereas seven studies (30%) [23][36][39][40][42][44][48] reported no significant effect (Table 2). Similarly, medication review (n = 8) and the provision of education (n = 4) were the most common interventions in these sixteen studies; however, these studies varied in their designs. There were 14 studies (87.5%) [22][30][33][34][37][38][39][41][42][43][45][46][47][48] that were of high quality, and of those, 11 studies [22][30][33][34][37][38][41][43][45][46][47] showed a significant reduction in anticholinergic prescribing errors. Seven studies had a follow-up period of ≥6 months, and four studies showed a significant reduction in anticholinergic prescribing errors. With a shorter follow-up period of 2 weeks to 6 months, 4 studies [37][43][46][47] out of 10 studies reported reductions in anticholinergic prescribing errors (Table 2).
Healthcare practitioner-oriented interventions that reported a significant reduction in anticholinergic prescribing errors included: medication review, education provision to healthcare practitioners, pharmacist-led electronic health record-based population health initiative and anticholinergic risk scale service, targeted patient-centred, pharmacist–physician team MTM intervention, context-aware pharmaceutical analysis tool, and SÄKLÄK project. Healthcare practitioner-oriented interventions were most effective in reducing ACB [21][29][35][49], DBI [22][37][43][45], and discontinuation or reduction of anticholinergic medications [30][33][34][38][41][46][47][50]. Hernandez et al. 2020 reported a decline in DBI from 1.38 (control group) to 1.08 (intervention group) [45]. Another study reported a reduction in ACB score from 1.08 (control group) to 0.89 (intervention group) [35]. A retrospective study by McLarin et al. [38] in Australia found a reduction in the mean scores of anticholinergic medications from 3.73 to 3.02 after implementing medication review.

3. Current Insights

In this work, medication review and education provision to the healthcare practitioners were the most common elements in many interventions. Medication review is a structured evaluation of patients’ pharmacotherapy to optimise drug use and reduce the occurrence of drug-related problems [51]. Similarly, medication review is recognised as an important healthcare practitioner-oriented intervention for reducing anticholinergic prescribing errors in older people [52]. Likewise, older people benefit mostly from medication reviews as this cohort is more susceptible to adverse drug effects [53][54]. The efficacy of medication review in reducing anticholinergic prescribing errors was reported by eight studies in this review [15][21][22][38][39][41][45][55]. Previous studies inform the significant effects of structured medication review on medication prescriptions and older adults’ quality of life [56][57][58].
Another intervention, such as the provision of education to the healthcare practitioners, was tested in eight studies, but only five studies reported the effectiveness of this intervention in reducing anticholinergic prescribing errors in older people [33][44][49][50][59]. Evidence informs that the healthcare practitioner-oriented educational intervention effectively reduces prescribing errors in older people [60][61]. The provision of education reduces the use of healthcare resources, including emergency department presentations and hospital admissions [62]. Implementing healthcare practitioner-led educational interventions encourages prescribers to change prescription practices, thus improving prescribers’ clinical practice [63]. An education intervention provides precise knowledge about prescribing in older adults, medication-related errors, and prevention strategies for reducing medication-related errors [63]. This review also showed that interventions such as INTERcheck, SÄKLÄK intervention model, targeted MTM intervention, context-aware pharmaceutical analysis tool, and CDSS alert were not successful in reducing anticholinergic prescribing errors in older adults [29][36][46][47][48].

References

  1. Buxton, I.L.O. Principles of Prescription Order Writing and Patient Compliance. In Goodman &amp, Gilman’s: The Pharmacological Basis of Therapeutics, 12th ed.; Brunton, L.L., Chabner, B.A., Knollmann, B.C., Eds.; McGraw-Hill Education: New York, NY, USA, 2015.
  2. Likic, R.; Maxwell, S.R. Prevention of medication errors: Teaching and training. Br. J. Clin. Pharmacol. 2009, 67, 656–661.
  3. Drag, L.L.; Wright, S.L.; Bieliauskas, L.A. Prescribing Practices of Anticholinergic Medications and Their Association with Cognition in an Extended Care Setting. J. Appl. Gerontol. 2012, 31, 239–259.
  4. Barton, C.; Sklenicka, J.; Sayegh, P.; Yaffe, K. Contraindicated medication use among patients in a memory disorders clinic. Am. J. Geriatr. Pharmacother. 2008, 6, 147–152.
  5. Buck, M.D.; Atreja, A.; Brunker, C.P.; Jain, A.; Suh, T.T.; Palmer, R.M.; Dorr, D.A.; Harris, C.M.; Wilcox, A.B. Potentially inappropriate medication prescribing in outpatient practices: Prevalence and patient characteristics based on electronic health records. Am. J. Geriatr. Pharmacother. 2009, 7, 84–92.
  6. Corsonello, A.; Pedone, C.; Lattanzio, F.; Lucchetti, M.; Garasto, S.; Di Muzio, M.; Giunta, S.; Onder, G.; Di Iorio, A.; Volpato, S.; et al. Potentially Inappropriate Medications and Functional Decline in Elderly Hospitalized Patients. J. Am. Geriatr. Soc. 2009, 57, 1007–1014.
  7. Hale, L.; Griffin, A.; Cartwright, O.; Moulin, J.; Alford, S.; Fleming, R. Potentially inappropriate medication use in hospitalized older adults: A DUE using the full Beers criteria. Formulary 2008, 43, 326–336.
  8. Rajska-Neumann, A.; Wieczorowska-Tobis, K. Polypharmacy and potential inappropriateness of pharmaco-logical treatment among community-dwelling elderly patients. Arch. Gerontol. Geriatr. 2007, 44 (Suppl. S1), 303–309.
  9. Gallagher, P.F.; Barry, P.J.; Ryan, C.; Hartigan, I.; O’Mahony, D. Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers’ Criteria. Age Ageing 2008, 37, 96–101.
  10. Ruxton, K.; Woodman, R.J.; Mangoni, A.A. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2015, 80, 209–220.
  11. Van Eijk, M.E.; Bahri, P.; Dekker, G.; Herings, R.M.; Porsius, A.; Avorn, J.; De Boer, A. Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. J. Clin. Epidemiol. 2000, 53, 645–651.
  12. Campbell, N.; Boustani, M.; Limbil, T.; Ott, C.; Fox, C.; Maidment, I.; Schubert, C.C.; Munger, S.; Fick, D.; Miller, D.; et al. The cognitive impact of anticholinergics: A clinical review. Clin. Interv. Aging 2009, 4, 225–233.
  13. Rudolph, J.L.; Salow, M.J.; Angelini, M.C.; McGlinchey, R.E. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch. Intern. Med. 2008, 168, 508–513.
  14. Kersten, H.; Wyller, T.B. Anticholinergic drug burden in older people’s brain—How well is it measured? Basic Clin. Pharmacol. Toxicol. 2014, 114, 151–159.
  15. Nishtala, P.S.; Salahudeen, M.S.; Hilmer, S.N. Anticholinergics: Theoretical and clinical overview. Expert Opin. Drug. Saf. 2016, 15, 753–768.
  16. Salahudeen, M.S.; Nishtala, P.S. Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. Drugs Aging 2016, 33, 305–313.
  17. Ali, S.; Peterson, G.M.; Bereznicki, L.R.; Salahudeen, M.S. Association between anticholinergic drug burden and mortality in older people: A systematic review. Eur. J. Clin. Pharmacol. 2020, 76, 319–335.
  18. Tune, L.E. Anticholinergic effects of medication in elderly patients. J. Clin. Psychiatry 2001, 62 (Suppl. S21), 11–14.
  19. Alharafsheh, A.; Alsheikh, M.; Ali, S.; Baraiki, A.A.; Alharbi, G.; Alhabshi, T.; Aboutaleb, A. A retrospective cross-sectional study of antibiotics prescribing patterns in admitted patients at a tertiary care setting in the KSA. Int. J. Health Sci. 2018, 12, 67–71.
  20. Gorup, E.; Rifel, J.; Petek Šter, M. Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients. Zdr Varst. 2018, 57, 140–147.
  21. Kersten, H.; Molden, E.; Tolo, I.K.; Skovlund, E.; Engedal, K.; Wyller, T.B. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: A randomized controlled trial. J. Gerontol. A. Biol. Sci. Med. Sci. 2013, 68, 271–278.
  22. Castelino, R.L.; Hilmer, S.N.; Bajorek, B.V.; Nishtala, P.; Chen, T.F. Drug Burden Index and potentially inappropriate medications in community-dwelling older people: The impact of Home Medicines Review. Drugs Aging 2010, 27, 135–148.
  23. Gnjidic, D.; Le Couteur, D.G.; Abernethy, D.R.; Hilmer, S.N. A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people. Ann. Pharmacother. 2010, 44, 1725–1732.
  24. Tay, H.S.; Soiza, R.L.; Mangoni, A.A. Minimizing anticholinergic drug prescribing in older hospitalized patients: A full audit cycle. Ther. Adv. Drug Saf. 2014, 5, 121–128.
  25. van der Meer, H.G.; Wouters, H.; Pont, L.G.; Taxis, K. Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: A randomised controlled trial. BMJ Open 2018, 8, e019042.
  26. Christensen, M.; Lundh, A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst. Rev. 2016, 2, Cd008986.
  27. Holland, R.; Desborough, J.; Goodyer, L.; Hall, S.; Wright, D.; Loke, Y.K. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2008, 65, 303–316.
  28. Wallerstedt, S.M.; Kindblom, J.M.; Nylén, K.; Samuelsson, O.; Strandell, A. Medication reviews for nursing home residents to reduce mortality and hospitalization: Systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2014, 78, 488–497.
  29. Moga, D.C.; Abner, E.L.; Rigsby, D.N.; Eckmann, L.; Huffmyer, M.; Murphy, R.R.; Coy, B.B.; Jicha, G.A. Optimizing medication appropriateness in older adults: A randomized clinical interventional trial to decrease anticholinergic burden. Alzheimers Res. Ther. 2017, 9, 36.
  30. Lenander, C.; Bondesson, Å.; Viberg, N.; Jakobsson, U.; Beckman, A.; Midlöv, P. Effects of an intervention (SÄKLÄK) on prescription of potentially inappropriate medication in elderly patients. Fam. Pract. 2017, 34, 213–218.
  31. Aronson, J.K. Medication errors: Definitions and classification. Br. J. Clin. Pharmacol. 2009, 67, 599–604.
  32. Velo, G.P.; Minuz, P. Medication errors: Prescribing faults and prescription errors. Br. J. Clin. Pharmacol. 2009, 67, 624–628.
  33. Starner, C.I.; Norman, S.A.; Reynolds, R.G.; Gleason, P.P. Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly. Am. J. Geriatr. Pharmacother. 2009, 7, 11–19.
  34. Carnahan, R.M.; Brown, G.D.; Letuchy, E.M.; Rubenstein, L.M.; Gryzlak, B.M.; Smith, M.; Reist, J.C.; Kelly, M.W.; Schultz, S.K.; Weckmann, M.T.; et al. Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes. Alzheimers Dement. 2017, 3, 553–561.
  35. Hanus, R.J.; Lisowe, K.S.; Eickhoff, J.C.; Kieser, M.A.; Statz-Paynter, J.L.; Zorek, J.A. Evaluation of a pharmacist-led pilot service based on the anticholinergic risk scale. J. Am. Pharm. Assoc. 2016, 56, 555–561.
  36. Boustani, M.A.; Campbell, N.L.; Khan, B.A.; Abernathy, G.; Zawahiri, M.; Campbell, T.; Tricker, J.; Hui, S.L.; Buckley, J.D.; Perkins, A.J.; et al. Enhancing care for hospitalized older adults with cognitive impairment: A randomized controlled trial. J. Gen. Intern. Med. 2012, 27, 561–567.
  37. Nishtala, P.S.; Hilmer, S.N.; McLachlan, A.J.; Hannan, P.J.; Chen, T.F. Impact of residential medication management reviews on drug burden index in aged-care homes: A retrospective analysis. Drugs Aging 2009, 26, 677–686.
  38. McLarin, P.E.; Peterson, G.M.; Curtain, C.M.; Nishtala, P.S.; Hannan, P.J.; Castelino, R.L. Impact of residential medication management reviews on anticholinergic burden in aged care residents. Curr. Med. Res. Opin. 2016, 32, 123–131.
  39. Weichert, I.; Romero-Ortuno, R.; Tolonen, J.; Soe, T.; Lebus, C.; Choudhury, S.; Nadarajah, C.V.; Nanayakkara, P.; Orrù, M.; Di Somma, S.; et al. Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study. J. Clin. Pharm. Ther. 2018, 43, 682–694.
  40. Juola, A.L.; Bjorkman, M.P.; Pylkkanen, S.; Finne-Soveri, H.; Soini, H.; Kautiainen, H.; Bell, J.S.; Pitkala, K.H. Nurse Education to Reduce Harmful Medication Use in Assisted Living Facilities: Effects of a Randomized Controlled Trial on Falls and Cognition. Drugs Aging 2015, 32, 947–955.
  41. Kersten, H.; Hvidsten, L.T.; Gløersen, G.; Wyller, T.B.; Wang-Hansen, M.S. Clinical impact of potentially inappropriate medications during hospitalization of acutely ill older patients with multimorbidity. Scand. J. Prim. Health Care 2015, 33, 243–251.
  42. Riordan, D.O.; Hurley, E.; Sinnott, C.; Galvin, R.; Dalton, K.; Kearney, P.M.; Halpin, J.D.; Byrne, S. Pharmacist-led academic detailing intervention in primary care: A mixed methods feasibility study. Int. J. Clin. Pharm. 2019, 41, 574–582.
  43. Ailabouni, N.; Mangin, D.; Nishtala, P.S. DEFEAT-polypharmacy: Deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int. J. Clin. Pharm. 2019, 41, 167–178.
  44. Toivo, T.; Airaksinen, M.; Dimitrow, M.; Savela, E.; Pelkonen, K.; Kiuru, V.; Suominen, T.; Uunimäki, M.; Kivelä, S.L.; Leikola, S.; et al. Enhanced coordination of care to reduce medication risks in older home care clients in primary care: A randomized controlled trial. BMC Geriatr. 2019, 19, 332.
  45. Hernandez, M.; Mestres, C.; Junyent, J.; Costa-Tutusaus, L.; Modamio, P.; Lastra, C.F.; Mariño, E.L. Effects of a multifaceted intervention in psychogeriatric patients: One-year prospective study. Eur. J. Hosp. Pharm. 2020, 27, 226–231.
  46. Lenander, C.; Bondesson, Å.; Viberg, N.; Beckman, A.; Midlöv, P. Effects of medication reviews on use of potentially inappropriate medications in elderly patients, a cross-sectional study in Swedish primary care. BMC Health Serv. Res. 2018, 18, 616.
  47. Lagrange, F.; Lagrange, J.; Bennaga, C.; Taloub, F.; Keddi, M.; Dumoulin, B. A context-aware decision-support system in clinical pharmacy: Drug monitoring in the elderly. Le Pharmacien Hospitalier et Clinicien 2017, 52, 100–110.
  48. Ghibelli, S.; Marengoni, A.; Djade, C.D.; Nobili, A.; Tettamanti, M.; Franchi, C.; Caccia, S.; Giovarruscio, F.; Remuzzi, A.; Pasina, L. Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (INTERcheck(®)). Drugs Aging 2013, 30, 821–828.
  49. Yeh, Y.C.; Liu, C.L.; Peng, L.N.; Lin, M.H.; Chen, L.K. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: A prospective cohort study. Geriatr. Gerontol. Int. 2013, 13, 694–700.
  50. van Eijk, M.E.; Avorn, J.; Porsius, A.J.; de Boer, A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: Randomised trial of group versus individual academic detailing. BMJ 2001, 322, 654–657.
  51. Øyane, N.M.F.; Finckenhagen, M.; Ruths, S.; Thue, G.; Lindahl, A.K. Improving drug prescription in general practice using a novel quality improvement model. Scand. J. Prim. Health Care. 2021, 39, 174–183.
  52. van der Meer, H.G.; Wouters, H.; van Hulten, R.; Pras, N.; Taxis, K. Decreasing the load? Is a Multidisciplinary Multistep Medication Review in older people an effective intervention to reduce a patient’s Drug Burden Index? Protocol of a randomised controlled trial. BMJ Open 2015, 5, e009213.
  53. Gurwitz, J.H.; Field, T.S.; Judge, J.; Rochon, P.; Harrold, L.R.; Cadoret, C.; Lee, M.; White, K.; LaPrino, J.; Erramuspe-Mainard, J.; et al. The incidence of adverse drug events in two large academic long-term care facilities. Am. J. Med. 2005, 118, 251–258.
  54. Martin, R.M.; Lunec, S.G.; Rink, E. UK postal survey of pharmacists working with general practices on prescribing issues: Characteristics, roles and working arrangements. Int. J. Pharm. Pract. 1998, 6, 133–139.
  55. Veggeland, T.; Dyb, S. The contribution of a clinical pharmacist to the improvement of medication at a geriatric hospital unit in Norway. Pharm. Pract. 2008, 6, 20–24.
  56. Romskaug, R.; Skovlund, E.; Straand, J.; Molden, E.; Kersten, H.; Pitkala, K.H.; Lundqvist, C.; Wyller, T.B. Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy: A Cluster Randomized Clinical Trial. JAMA Intern. Med. 2020, 180, 181–189.
  57. Gallagher, P.F.; O’Connor, M.N.; O’Mahony, D. Prevention of potentially inappropriate prescribing for elderly patients: A randomized controlled trial using STOPP/START criteria. Clin. Pharmacol. Ther. 2011, 89, 845–854.
  58. Clyne, B.; Smith, S.M.; Hughes, C.M.; Boland, F.; Bradley, M.C.; Cooper, J.A.; Fahey, T. Effectiveness of a Multifaceted Intervention for Potentially Inappropriate Prescribing in Older Patients in Primary Care: A Cluster-Randomized Controlled Trial (OPTI-SCRIPT Study). Ann. Fam. Med. 2015, 13, 545–553.
  59. Pasina, L.; Marengoni, A.; Ghibelli, S.; Suardi, F.; Djade, C.D.; Nobili, A.; Franchi, C.; Guerrini, G. A Multicomponent Intervention to Optimize Psychotropic Drug Prescription in Elderly Nursing Home Residents: An Italian Multicenter, Prospective, Pilot Study. Drugs Aging 2016, 33, 143–149.
  60. Riordan, D.O.; Walsh, K.A.; Galvin, R.; Sinnott, C.; Kearney, P.M.; Byrne, S. The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: A systematic review. SAGE Open Med. 2016, 4, 2050312116652568.
  61. Jaam, M.; Naseralallah, L.M.; Hussain, T.A.; Pawluk, S.A. Pharmacist-led educational interventions provided to healthcare providers to reduce medication errors: A systematic review and meta-analysis. PLoS ONE 2021, 16, e0253588.
  62. García-Gollarte, F.; Baleriola-Júlvez, J.; Ferrero-López, I.; Cuenllas-Díaz, Á.; Cruz-Jentoft, A.J. An educational intervention on drug use in nursing homes improves health outcomes resource utilization and reduces inappropriate drug prescription. J. Am. Med. Dir. Assoc. 2014, 15, 885–891.
  63. Trivalle, C.; Cartier, T.; Verny, C.; Mathieu, A.M.; Davrinche, P.; Agostini, H.; Becquemont, L.; Demolis, P. Identifying and preventing adverse drug events in elderly hospitalised patients: A randomised trial of a program to reduce adverse drug effects. J. Nutr. Health Aging 2010, 14, 57–61.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Geriatrics & Gerontology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mohammed S Salahudeen
View Times: 431
Revisions: 3 times (View History)
Update Date: 08 Feb 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback